Barclays
AMPE

Barclays’s Ampio Pharmaceuticals Inc. AMPE Stock Holding History

Barclays’s Portfolio AMPE Stock Details AMPE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-267
Closed -$272K – 7419
2018
Q1 		$272K Buy
+267
New +$224K ﹤0.01% 4561
2015
Q2 		– Sell
-333
Closed -$700K – 7279
2015
Q1 		$700K Buy
+333
New +$568K ﹤0.01% 3287

Other funds holding AMPE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCMC
Private Capital Management (Colorado) Denver, Colorado $501M AUM 17.09% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Barclays's AMPE Position: Q2 2022 in Review

Barclays sold out of Ampio Pharmaceuticals Inc. (AMPE) in Q2 2022, closing a stake of 143 shares — an estimated $20K sold.

Barclays first reported a position in AMPE in Q2 2013 and held it in 23 quarters. The position peaked at $406K in Q1 2015. 111 funds tracked by Wall St. Rank hold AMPE as of Q2 2022.

  • Barclays reported no remaining Ampio Pharmaceuticals Inc. position as of Q2 2022 after selling out during the quarter.
  • Barclays sold 143 Ampio Pharmaceuticals Inc. shares in Q2 2022, an estimated $20K.
  • Barclays first reported a position in Ampio Pharmaceuticals Inc. in Q2 2013 and held it in 23 quarters.
  • Barclays's Ampio Pharmaceuticals Inc. position peaked at $406K in Q1 2015.
  • 111 funds tracked by Wall St. Rank held Ampio Pharmaceuticals Inc. as of Q2 2022.

Based on Barclays's 13F filing for Q2 2022, filed 12 Aug 2022.